UNLOCKING

CARDIOLOGY

IMMUNOLOGY

HEaLTHCARE

Life

We aim to create a lasting and meaningful impact on patients suffering from cardiac conditions.

Cardiovascular diseases are a major burden and the first cause of death globally.

18₊

Millions
deaths/year

85_%

caused by myocardial infarction
& stroke

300

millions Disability-adjusted
life years (DALY)

We unlock the potential of immunotherapies to reshape the future of Cardiovascular care.

Our revolution

Patients

We aim to drastically reduce the burden of cardiovascular diseases by providing early-stage treatment to patients, thereby mitigating the damage inflicted to the heart.

Technology

We designed a first in class monoclonal antibody that specifically targets the immune system to prevent cardiac damage in ischemic cardiovascular diseases.

about POLYGON

Polygon emerges from cutting-edge academic research. The project is led by three co-founders with complementary backgrounds, all geared up to bring innovation from bench to patients' bed in a fresh, bold and committed approach.

NEWS

Our Latest news

Prof. Hafid Ait-Oufella recognized and honored by the French Academy of Sciences

November 26, 2024

Polygon Therapeutics shares recent achievements and acceleration for a First In Human in 2025

November 8, 2024

Co-founder Tatiana Monseur named among Forbes Women 2024

July 4, 2024